FDA grants orphan drug status to Papillon Therapeutics’ PPL-001
This designation will offer potential benefits such as tax credits and fee waivers to facilitate the drug’s development. The ODD status is intended for potential treatments for diseases
RA Capital Management spearheaded the financing round with contributions from current investors namely Insight Partners, NVentures and Gaingels. New participants in this funding round included Catalio Capital Management,